Role of interleukin-1 receptor 1/MyD88 signalling in the development and progression of pulmonary hypertension

European Respiratory Journal

Volumn 48, Issue 2, 2016, Pages 470-483

  Parpaleix, Aurélien ^a   Amsellem, Valérie ^a   Houssaini, Amal ^a   Abid, Shariq ^a   Breau, Marielle ^a   Marcos, Elisabeth ^a   Sawaki, Daigo ^a   Delcroix, Marion ^b   Quarck, Rozenn ^b   Maillard, Aurélie ^c   Couillin, Isabelle ^c   Ryffel, Bernhard ^c   Adnot, Serge ^a  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITÉ D'ORLÉANS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCROTALINE; MYELOID DIFFERENTIATION FACTOR 88; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; IL1R1 PROTEIN, HUMAN; IL1R1 PROTEIN, MOUSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MYD88 PROTEIN, HUMAN; MYD88 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG MECHANISM; GENE DELETION; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; LUNG ALVEOLUS MACROPHAGE; LUNG PARENCHYMA; MOUSE; NONHUMAN; PATHOGENESIS; PERIVASCULAR SPACE; PNEUMONIA; PRIORITY JOURNAL; PROTECTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; RAT; SIGNAL TRANSDUCTION; TISSUE LEVEL; ANIMAL; C57BL MOUSE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMISTRY; CONDITIONED MEDIUM; INFLAMMATION; MACROPHAGE; METABOLISM; SMOOTH MUSCLE CELL; TRANSGENIC MOUSE; WISTAR RAT;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; GENE DELETION; HUMANS; HYPERTENSION, PULMONARY; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MONOCROTALINE; MYELOID DIFFERENTIATION FACTOR 88; MYOCYTES, SMOOTH MUSCLE; NF-KAPPA B; RATS; RATS, WISTAR; RECEPTORS, INTERLEUKIN-1 TYPE I; SIGNAL TRANSDUCTION;

EID: 84979993017     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01448-2015     Document Type: Article

References (35)

1. Rabinovitch M, Guignabert C, Humbert M, et al. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res 2014; 115: 165-175.
2. Perros F, Dorfmüller P, Souza R, et al. Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. Eur Respir J 2007; 29: 462-468.
3. Savai R, Pullamsetti SS, Kolbe J, et al. Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 186: 897-908.
4. Amsellem V, Lipskaia L, Abid S, et al. CCR5 as a treatment target in pulmonary arterial hypertension. Circulation 2014; 130: 880-891.
5. Morrell NW, Adnot S, Archer SL, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S20-S31.
6. Price LC, Wort SJ, Perros F, et al. Inflammation in pulmonary arterial hypertension. Chest 2012; 141: 210-221.
7. Hassoun PM, Mouthon L, Barber? JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009; 54: S10-S19.
8. Vergadi E, Chang MS, Lee C, et al. Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension. Circulation 2011; 123: 1986-1995.
9. Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140: 821-832.
10. Lin Q, Li M, Fang D, et al. The essential roles of Toll-like receptor signaling pathways in sterile inflammatory diseases. Int Immunopharmacol 2011; 11: 1422-1432.
11. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β. Mol Cell 2002; 10: 417-426.
12. Dinarello CA. A clinical perspective of IL-1β as the gatekeeper of inflammation. Eur J Immunol 2011; 41: 1203-1217.
13. Dinarello CA. Interleukin-1. Cytokine Growth Factor Rev 1997; 8: 253-265.
14. Arend WP, Guthridge CJ. Biological role of interleukin 1 receptor antagonist isoforms. Ann Rheum Dis 2000; 59: Suppl. 1, i60-i64.
15. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Ann Rev Immunol 2009; 27: 519-550.
16. Warner N, N?ñez G. MyD88: a critical adaptor protein in innate immunity signal transduction. J Immunol 2013; 190: 3-4.
17. Muzio M, Ni J, Feng P, et al. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 1997; 278: 1612-1615.
18. Dunne A, O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE 2003; 2003: re3.
19. O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev 2008; 226: 10-18.
20. Houssaini A, Abid S, Mouraret N, et al. Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension. Am J Respir Cell Mol Biol 2013; 48: 568-577.
21. Li P, Li YL, Li ZY, et al. Cross talk between vascular smooth muscle cells and monocytes through interleukin-1β/interleukin-18 signaling promotes vein graft thickening. Arterioscler Thromb Vasc Biol 2014; 34: 2001-2011.
22. Liu PL, Liu JT, Kuo HF, et al. Epigallocatechin gallate attenuates proliferation and oxidative stress in human vascular smooth muscle cells induced by interleukin-1β via heme oxygenase-1. Mediators Inflamm 2014; 2014: 523684.
23. Bauer EM, Shapiro R, Zheng H, et al. High mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of Toll-like receptor 4. Mol Med 2013; 18: 1509-1518.
24. Bauer EM, Chanthaphavong RS, Sodhi CP, et al. Genetic deletion of toll-like receptor 4 on platelets attenuates experimental pulmonary hypertension. Circ Res 2014; 114: 1596-1600.
25. Voelkel NF, Tuder RM, Bridges J, et al. Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline. Am J Respir Cell Mol Biol 1994; 11: 664-675.
26. Campos M, Schiopu E. Pulmonary arterial hypertension in adult-onset Still's disease: rapid response to anakinra. Case Rep Rheumatol 2012; 2012: 537613.
27. Labow M, Shuster D, Zetterstrom M, et al. Absence of IL-1 signaling and reduced inflammatory response in IL-1 type I receptor-deficient mice. J Immunol 1997; 159: 2452-2461.
28. Kawai T, Adachi O, Ogawa T, et al. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 1999; 11: 115-122.
29. Guignabert C, Izikki M, Tu LI, et al. Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res 2006; 98: 1323-1330.
30. Dinarello CA, Ikejima T, Warner SJ, et al. Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol 1987; 139: 1902-1910.
31. Zsebo KM, Wypych J, Yuschenkoff VN, et al. Effects of hematopoietin-1 and interleukin 1 activities on early hematopoietic cells of the bone marrow. Blood 1988; 71: 962-968.
32. Zsebo KM, Yuschenkoff VN, Schiffer S, et al. Vascular endothelial cells and granulopoiesis: interleukin-1 stimulates release of G-CSF and GM-CSF. Blood 1988; 71: 99-103.
33. Khallou-Laschet J, Varthaman A, Fornasa G, et al. Macrophage plasticity in experimental atherosclerosis. PloS One 2010; 5: e8852.
34. Zhang H, Downs EC, Lindsey JA, et al. Interactions between the monocyte/macrophage and the vascular smooth muscle cell. Stimulation of mitogenesis by a soluble factor and of prostanoid synthesis by cell-cell contact. Arterioscler Thromb 1993; 13: 220-230.
35. Gillespie MN, Goldblum SE, Cohen DA, et al. Interleukin 1 bioactivity in the lungs of rats with monocrotalineinduced pulmonary hypertension. Proc Soc Exp Biol Med 1988; 187: 26-32.